Interleukine-6 in the Bone Marrow Microenvironment: A Good Target to Stop the Progression of Multiple Myeloma. A Promising Perspective

Maria Benito

IPN Communications, Dublin, Ireland

Dr. Maria Benito, IPN Communications, Dublin, Ireland.

Keywords: Bone Marrow; Multiple Myeloma; Interleukine-6

Abstract

Multiple myeloma (MM) is a malignant lymphoproliferative disorder of unknown etiology. Risk factors - including ionizing radiation and chemicals - and genetic factors play a major role in the onset and development [1]. The clinical presentation at onset differs from completely asymptomatic with no evidence of organ damage to an acute life threatening condition. Despite the advancement of many therapeutic agents that have considerably improved the overall survival of patients, MM continues being an incurable disease. Regardless of stem cell transplantation and novel therapies, the vast majority of patients with MM will eventually relapse and become refractory to standard therapy. Besides the genetic heterogeneity, the interaction between myeloma cells and cancer microenvironment is partly responsible for the failure of treatments.

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).